Dr. Ruby Sharma, M.D
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,980 | 2 | 74.3% |
| Travel and Lodging | $944.39 | 2 | 17.6% |
| Food and Beverage | $418.76 | 1 | 7.8% |
| Education | $11.92 | 1 | 0.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $3,980 | 2 | $0 (2024) |
| Roche Products Limited | $1,363 | 3 | $0 (2018) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,980 | 2 | Eli Lilly and Company ($3,980) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2018 | $1,363 | 3 | Roche Products Limited ($1,363) |
All Payment Transactions
6 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $3,946.00 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 08/23/2024 | Eli Lilly and Company | — | — | In-kind items and services | $34.45 | Research |
| Study: EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/09/2018 | Roche Products Limited | TECENTRIQ (Biological) | Travel and Lodging | In-kind items and services | $616.87 | General |
| Category: BioOncology | ||||||
| 05/09/2018 | Roche Products Limited | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $418.76 | General |
| Category: BioOncology | ||||||
| 05/09/2018 | Roche Products Limited | TECENTRIQ (Biological) | Travel and Lodging | In-kind items and services | $327.52 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $3,980 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 335 | 606 | $457,668 | $74,570 |
| 2022 | 7 | 394 | 627 | $476,310 | $84,718 |
| 2021 | 8 | 400 | 624 | $346,569 | $82,069 |
| 2020 | 8 | 386 | 596 | $307,765 | $62,091 |
All Medicare Procedures & Services
29 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 148 | 291 | $200,499 | $31,797 | 15.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 46 | 154 | $150,766 | $24,749 | 16.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 45 | 45 | $39,555 | $7,121 | 18.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 57 | 68 | $33,592 | $5,144 | 15.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $24,240 | $3,737 | 15.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 28 | $9,016 | $2,023 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 137 | 256 | $176,384 | $29,498 | 16.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 49 | 149 | $145,871 | $25,542 | 17.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 64 | 65 | $57,135 | $12,142 | 21.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 35 | 35 | $42,420 | $7,538 | 17.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 58 | 66 | $32,604 | $5,429 | 16.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 23 | 28 | $12,880 | $2,695 | 20.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 28 | $9,016 | $1,875 | 20.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 45 | 158 | $101,278 | $26,347 | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 143 | 218 | $103,458 | $25,779 | 24.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 71 | 73 | $64,167 | $13,708 | 21.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $20,218 | $4,797 | 23.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 49 | 54 | $20,682 | $3,949 | 19.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 36 | 58 | $18,676 | $3,838 | 20.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 22 | 27 | $12,420 | $2,503 | 20.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 12 | 14 | $5,670 | $1,148 | 20.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 152 | 233 | $110,675 | $21,613 | 19.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 52 | 130 | $83,330 | $16,344 | 19.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 43 | 44 | $38,676 | $8,489 | 21.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 53 | 90 | $28,980 | $6,158 | 21.2% |
About Dr. Ruby Sharma, M.D
Dr. Ruby Sharma, M.D is a Student in an Organized Health Care Education/Training Program healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1750589701.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ruby Sharma, M.D has received a total of $5,356 in payments from pharmaceutical and medical device companies, with $3,980 received in 2024. These payments were reported across 6 transactions from 3 companies. The most common payment nature is "" ($3,980).
As a Medicare-enrolled provider, Sharma has provided services to 1,515 Medicare beneficiaries, totaling 2,453 services with total Medicare billing of $303,449. Data is available for 4 years (2020–2023), covering 29 distinct procedure/service records.
Practice Information
- Specialty Student in an Organized Health Care Education/Training Program
- Other Specialties Internal Medicine, Hematology & Oncology
- Location New Hyde Park, NY
- Active Since 07/10/2007
- Last Updated 06/26/2015
- Taxonomy Code 390200000X
- Entity Type Individual
- NPI Number 1750589701
Products in Payments
- TECENTRIQ (Biological) $1,363
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Student in an Organized Health Care Education/Training Program Doctors in New Hyde Park
Dr. Jeffrey Silpe, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $47,248
Haisam Ismail, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $38,425
Whitney Bowe, M.d, M.D
Student in an Organized Health Care Education/Training Program — Payments: $36,934
Stephen Lu
Student in an Organized Health Care Education/Training Program — Payments: $15,950
Dr. Jeffrey Goldstein, Md, MD
Student in an Organized Health Care Education/Training Program — Payments: $10,227
Michael Mazer
Student in an Organized Health Care Education/Training Program — Payments: $10,042